Dr. Douglas Trask, MD, PhD, an otolaryngologist at the world-renowned Cleveland Clinic, visited China to present at the 15th National Scientific Meeting of Chinese Society of Otolaryngology – Head and Neck Surgery.
The meeting was hosted at the Xiamen International Conference & Exhibition Center (XICEC) which boasts its scenic location and proximity to public transportation. With 3,000+ Chinese ENTs in attendance, the center served as a venue for collaborative efforts in advancing ENT treatment and the introduction of innovative technology.
On October 13th, Dr. Trask addressed the importance of identifying the laryngopharyngeal disease state and treating with evidence-based results instead of empirical treatment. In his presentation, Diagnosis and Treatment of Gastroesophageal Reflux and Pharyngeal Reflux Disease, he provided evidence for Restech’s role in obtaining a definitive diagnosis of laryngopharyngeal reflux disease.
“I was honored to speak on behalf of Restech at the Society Meeting…The presentation on LPR/Atypical Reflux was well received by the audience of over 100 ENT's,” Dr. Trask explained. “Following the presentation, there was a lively discussion on the merits of ambulatory pH testing prior to empirically treating the patients with a 8–12 week PPI trial. The physicians came away with a greater understanding of the role Restech can play in the clinician’s diagnosis of LPR.”
Restech develops and markets transformative diagnostic technologies to accurately diagnose and better manage reflux. Restech’s patented technology is employed throughout the US and globally, providing greater patient comfort, simple in-office placement, and highly accurate results. These unique diagnostic tools are helping to evolve the standard of care for patients with reflux, providing physicians with the necessary data to transform the algorithm of care for millions of patients.
For more information on the Dx-pH Measurement System, please Call 800.352.1512 or visit www.restech.com.